PDF(Sci-hub)
Abstract：
To investigate if eyes presenting intraocular pressure (IOP) within the limits of current guideline-driven target IOP indeed experience slow rates of glaucomatous visual field (VF) progression.
A total of 8598 24-2 VF tests from 603 eyes from the African Descent and Glaucoma Evaluation Study with manifest glaucoma were included. The sample was split into three groups based on baseline VF mean deviation (MD): G1 (better than -5.0 dB), G2 (-5.0 to -10 dB) and G3 (worse than -10 dB). We investigated the relationship between existing target IOP guidelines and rates of MD progression in these groups.
For stable eyes, the medians and IQR of the mean follow-up IOP were G1=15.0 mmHg (IQR: 13.1 to 17.7), G2=13.2 mmHg (IQR: 11.6 to 14.3) and G3=11.9 mmHg (IQR: 10.1 to 13.8) (p<0.01). When considering the mean follow-up IOP within the limits proposed by current guidelines, the median MD slopes were: -0.20 dB/y (IQR: -0.43 to -0.02) for G1<21 mmHg, -0.19 dB/y (IQR: -0.51 to -0.01) for G2<18 mmHg and -0.15 dB/y (IQR: -0.47 to 0.05) for G3<15 mmHg (p=0.63). There were no significant differences between racial groups.
In a sample of patients with manifest glaucoma, despite substantial variability between eyes, adherence to treatment guidelines helped slow the rates of global VF progression at various stages of disease.
clinicaltrials.gov Identifier: NCT00221923.
A total of 8598 24-2 VF tests from 603 eyes from the African Descent and Glaucoma Evaluation Study with manifest glaucoma were included. The sample was split into three groups based on baseline VF mean deviation (MD): G1 (better than -5.0 dB), G2 (-5.0 to -10 dB) and G3 (worse than -10 dB). We investigated the relationship between existing target IOP guidelines and rates of MD progression in these groups.
For stable eyes, the medians and IQR of the mean follow-up IOP were G1=15.0 mmHg (IQR: 13.1 to 17.7), G2=13.2 mmHg (IQR: 11.6 to 14.3) and G3=11.9 mmHg (IQR: 10.1 to 13.8) (p<0.01). When considering the mean follow-up IOP within the limits proposed by current guidelines, the median MD slopes were: -0.20 dB/y (IQR: -0.43 to -0.02) for G1<21 mmHg, -0.19 dB/y (IQR: -0.51 to -0.01) for G2<18 mmHg and -0.15 dB/y (IQR: -0.47 to 0.05) for G3<15 mmHg (p=0.63). There were no significant differences between racial groups.
In a sample of patients with manifest glaucoma, despite substantial variability between eyes, adherence to treatment guidelines helped slow the rates of global VF progression at various stages of disease.
clinicaltrials.gov Identifier: NCT00221923.
摘要：
调查在当前指南驱动的目标IOP范围内出现眼内压（IOP）的眼睛是否确实经历了青光眼视野（VF）进展缓慢的速度。
包括来自具有明显青光眼的非洲血统和青光眼评估研究的603只眼的总共8598个24-2VF测试。根据基线VF平均偏差（MD）将样本分为三组：G1（优于-5.0dB），G2（-5.0到-10dB）和G3（比-10dB差）。我们调查了这些组中现有的目标IOP指南与MD进展率之间的关系。
对于稳定的眼睛，平均随访眼压的中位数和IQR为G1=15.0mmHg（IQR：13.1至17.7），G2=13.2mmHg(IQR:11.6至14.3)和G3=11.9mmHg(IQR:10.1至13.8)(p<0.01)。在当前指南建议的范围内考虑平均随访IOP时，对于G1<21mmHg，MD斜率中位数为：-0.20dB/y（IQR：-0.43至-0.02），对于G2<18mmHg，为-0.19dB/y（IQR：-0.51至-0.01），对于G3<15mmHg（p=0.63），为-0.15dB/y（IQR：-0.47至0.05）。种族之间没有显着差异。
在明显青光眼患者的样本中，尽管眼睛之间有很大的差异，坚持治疗指南有助于减缓不同疾病阶段的整体VF进展速度.
clinicaltrials.gov标识符：NCT00221923。
包括来自具有明显青光眼的非洲血统和青光眼评估研究的603只眼的总共8598个24-2VF测试。根据基线VF平均偏差（MD）将样本分为三组：G1（优于-5.0dB），G2（-5.0到-10dB）和G3（比-10dB差）。我们调查了这些组中现有的目标IOP指南与MD进展率之间的关系。
对于稳定的眼睛，平均随访眼压的中位数和IQR为G1=15.0mmHg（IQR：13.1至17.7），G2=13.2mmHg(IQR:11.6至14.3)和G3=11.9mmHg(IQR:10.1至13.8)(p<0.01)。在当前指南建议的范围内考虑平均随访IOP时，对于G1<21mmHg，MD斜率中位数为：-0.20dB/y（IQR：-0.43至-0.02），对于G2<18mmHg，为-0.19dB/y（IQR：-0.51至-0.01），对于G3<15mmHg（p=0.63），为-0.15dB/y（IQR：-0.47至0.05）。种族之间没有显着差异。
在明显青光眼患者的样本中，尽管眼睛之间有很大的差异，坚持治疗指南有助于减缓不同疾病阶段的整体VF进展速度.
clinicaltrials.gov标识符：NCT00221923。
